Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 35 of 37, showing 5 Applications out of 181 total, starting on record 171, ending on 175

# Protocol No Study Title Investigator(s) & Site(s)

171.

ECCT/23/12/02   PEARL RSVt Vaccine Study
    Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL)   
Principal Investigator(s)
1. Dr. Maricianah Onono
Site(s) in Kenya
1. Victoria Biomedical Research Institute (VIBRI) (Kisumu county)
2. Walter Reed Army Institute of Research -Kericho Site (Kericho county)
3. KEMRI CCR – Butere Clinical Research Centre (Kakamega county)
4. Siaya County Referral Hospital (SCRH) (Siaya county)
5. Kenya Medical Research Institute Center for Microbiology Research (CMR) (Kisumu county)
6. KAVI - Institute of Clinical Research (KAVI - ICR) (Nairobi City county)
7. Kombewa Clinical Research Center, KEMRI, (Kisumu county)
 
View

172.

ECCT/14/09/02   LIVING STUDY-PHASE III B.
    Prospective study of Lopinavir based ART for HIVInfected childreNGlobally (LIVING study)   
Principal Investigator(s)
1. Elizabeth Maleche Obimbo
2. Elizabeth Bukusi
3. Winstone Nyandiko
4. Bienvenu Baruani Ngoy
5. Joseph Kariuki Mbuthia
6. Allan Godfrey Otieno
7. Lucy Koech
8. Neema Mturi
9. Beatrice Mutai
Site(s) in Kenya
1. University of Nairobi/ Kenyatta National Hospital (Nairobi City county)
2. AMPATH, Moi University Teaching and Referral Hospital Eldoret (Uasin Gishu county)
3. MSF Belgium Kibera Clinic (Nairobi City county)
4. Gertrude\'s Children\'s Hospital (Nairobi City county)
5. Mbagathi District Hospital (Nairobi City county)
 
View

173.

ECCT/08/27/12   MAL 55: A phase III, double blind (observer-blind), randomised, controlled multicenter study to evaluate, in infants and children, the efficacy of the RTS,S/AS01E candidate vaccine against malaria disease caused by P. falciparum infection.
    Protocol No. 110021 - MAL 55 STUDY   A phase III, double blind (observer-blind), randomised, controlled multicenter study to evaluate, in infants and children, the efficacy of the RTS,S/AS01E candidate vaccine against malaria disease caused by P. falciparum infection, across diverse malaria transmission settings in Africa”   
Principal Investigator(s)
1. Dr. Mary Hamel
2. Dr. Patricia Njuguna
3. Dr. Walter Otieno
Site(s) in Kenya
1. KEMRI - CDC RESEARCH INSTITUTION CENTRE, KISUMU (Kisumu county)
2. KEMRI-WELLCOME TRUST RESEARCH CENTER, KILIFI SITE (Kilifi county)
3. KEMRI-WALTERREED, RESEARCH CENTRE, KOMBEWA SITE (Kisumu county)
 
View

174.

ECCT/15/06/01  
    Pyronaridine-artesunate and artemether-lumefantrine for the treatment of paediatric uncomplicated falciparum malaria in Western Kenya   
Principal Investigator(s)
1. Patrick Sawa
Site(s) in Kenya
St. Judes Clinic, ICIPE
 
View

175.

ECCT/12/09/02   Reduction of EArly mortaLITY in adults and children
    Reduction of EArly mortaLITY in HIVinfected adults and children starting antiretroviral therapy (REALITY)   
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
2. KEMRI Wellcome Trust Research Programme (Kilifi county)
 
View